AtriCure (ATRC) Stock Price, News & Analysis

Company Overview

AtriCure, Inc. is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products. AtriCure also offers the EPi-Sense system for hybrid and minimally invasive AFib procedures, as well as products used in cardiac and thoracic pain-management procedures.

Founded in 2000 and headquartered in Mason, Ohio, AtriCure serves hospitals and medical professionals in the United States and international markets. Its products are marketed for use in open, minimally invasive and hybrid surgical approaches, with the company focused on expanding treatment options for patients with AFib and other heart-rhythm disorders.

Key Stats

• Today's Range: $58.26 to $61.11
• 50-Day Range: $48.35 to $65.53
• 52-Week Range: $25.36 to $66.02
• Volume: 614,651 shs
• Average Volume: 791,495 shs
• Market Capitalization: $2.98 billion
• P/E Ratio: 142.78
• Dividend Yield: N/A
• Price Target: $61.80
• Consensus Rating: Moderate Buy

AtriCure Stock Analysis - MarketRank™

AtriCure scored higher than 47% of companies evaluated by MarketBeat, and ranked 540th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for AtriCure is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

AtriCure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 13.64%

Earnings Growth

Earnings for AtriCure are expected to grow by 13.64% in the coming year, from $0.44 to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AtriCure is 142.78, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.99.

Price to Earnings Ratio vs. Sector

The P/E ratio of AtriCure is 142.78, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.57.

Price to Book Value per Share Ratio

AtriCure has a P/B Ratio of 5.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.01% of the float of AtriCure has been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 5.21.

Change versus previous month

Short interest in AtriCure has recently increased by 1.40%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AtriCure does not currently pay a dividend.

Dividend Growth

AtriCure does not have a long track record of dividend growth.

News and Social Media

• Score: 4.1 / 5
• News Sentiment: 0.57

News Sentiment

AtriCure has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for AtriCure this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for ATRC on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added AtriCure to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,172,263.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of AtriCure is held by insiders.

Percentage Held by Institutions

99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/03/2026
• Today: 11/07/2026
• UBS Global Healthcare Conference: 11/09/2026
• Stifel 2026 Healthcare Conference 2026: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ATRC
• CIK: 1323885
• Web: www.atricure.com
• Phone: (513) 755-4100
• Fax: 513-755-4567
• Employees: 1,350
• Year Founded: 2000

Price Target and Rating

• Average Price Target for AtriCure: $61.80
• High Price Target: $70.00
• Low Price Target: $44.00
• Potential Upside/Downside: +5.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.30
• Trailing P/E Ratio: 142.78
• Forward P/E Ratio: 117.08
• P/E Growth: N/A
• Net Income: -$11.45 million
• Net Margins: 2.52%
• Pretax Margin: 2.75%
• Return on Equity: 4.01%
• Return on Assets: 3.03%

Debt

• Debt-to-Equity Ratio: 0.17
• Current Ratio: 4.33
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $534.53 million
• Price / Sales: 5.58
• Cash Flow: $0.31 per share
• Price / Cash Flow: 187.03
• Book Value: $10.47 per share
• Price / Book: 5.59

Miscellaneous

• Outstanding Shares: 50,920,000
• Free Float: 48,885,000
• Market Cap: $2.98 billion
• Optionable: Optionable
• Beta: 1.23